Targets for Neoadjuvant Therapy - The Preferences of Patients with Early Breast Cancer.

ABSTRACT: Background: Therapists and administrative bodies consider a pathological complete remission as an independent and relevant endpoint in evaluations of the clinical utility of neoadjuvant therapy for early breast cancer. The present study aims to investigate which treatment outcomes of a neoadjuvant therapy are considered by the patients themselves to be relevant. Materials and Methods: With the help of analytic hierarchy process (AHP) methods patient preferences about the treatment targets of neoadjuvant therapy were assessed quantitatively. All participants had undergone a neoadjuvant therapy in the form of chemotherapy and, in HER2-positive cases, as a targeted antibody therapy against HER2 for the primary diagnosis of early breast cancer 12-36 months prior to the interview.

SUBMITTER: Thill M 

PROVIDER: S-EPMC4873298 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature